Periodic Reporting for period 1 - MOHEDD (Metal-Organic Hydrogels for Efficient Drug Delivery (MOHEDD))
Periodo di rendicontazione: 2020-11-01 al 2023-04-30
The MOHEDD project tackles the challenge of treating hard-to-treat cancers, including pancreatic cancer, mesothelioma, and glioblastoma, but also less aggressive ones such as breast cancer, by pioneering advanced drug delivery systems. Through the integration of metal-organic frameworks (MOFs) and hydrogel hybrids, MOHEDD seeks to enhance the efficiency and precision of drug delivery while minimising side effects associated with conventional chemotherapy. This initiative aimed to accelerate the development of these cutting-edge nanoparticles and hydrogels into highly efficient delivery vehicles for cancer therapies.
At the heart of MOHEDD's innovation lies the combination of nanoMOF particles and hydrogel networks. By integrating MOFs loaded with cancer drugs within a hydrogel matrix, we created a biocompatible and customisable system for controlled drug delivery. The 3D sponge-like networks of hydrogels not only promote the dispersibility of MOFs but also facilitate the precise tuning of the hydrogel properties. This integration offers the potential to achieve higher local drug concentrations and fewer side effects, addressing the limitations of existing local chemotherapy approaches.
The project's impact was significantly amplified through strong collaboration with industrial partners and clinical advisors. By conducting in vitro studies to validate drug loading and release with MOF@hydrogels, MOHEDD laid the foundation for evaluating the efficacy and potential of these innovative composites. The culmination of these efforts resulted in the formation of Vector Bioscience Cambridge Ltd, a spin-out company from the University of Cambridge. Vector Bioscience has continued he activities from MOHEDD, translating the developed nanoMOFs into real, clinical solutions.
The project's achievements were further underscored by securing a €2.5 million EIC Transition Challenge award in 2023. This milestone not only underscores the recognition of MOHEDD's potential but also positions Vector Bioscience for further advancements in bringing novel drug delivery technologies to the forefront of cancer treatment. MOHEDD's journey highlights the collaborative spirit of innovation, merging academia, industry, and clinical expertise to propel cancer therapy into an era of enhanced precision, efficacy, and patient outcomes.
At the heart of MOHEDD's innovation lies the combination of nanoMOF particles and hydrogel networks. By integrating MOFs loaded with cancer drugs within a hydrogel matrix, we created a biocompatible and customisable system for controlled drug delivery. The 3D sponge-like networks of hydrogels not only promote the dispersibility of MOFs but also facilitate the precise tuning of the hydrogel properties. This integration offers the potential to achieve higher local drug concentrations and fewer side effects, addressing the limitations of existing local chemotherapy approaches.
The project's impact was significantly amplified through strong collaboration with industrial partners and clinical advisors. By conducting in vitro studies to validate drug loading and release with MOF@hydrogels, MOHEDD laid the foundation for evaluating the efficacy and potential of these innovative composites. The culmination of these efforts resulted in the formation of Vector Bioscience Cambridge Ltd, a spin-out company from the University of Cambridge. Vector Bioscience has continued he activities from MOHEDD, translating the developed nanoMOFs into real, clinical solutions.
The project's achievements were further underscored by securing a €2.5 million EIC Transition Challenge award in 2023. This milestone not only underscores the recognition of MOHEDD's potential but also positions Vector Bioscience for further advancements in bringing novel drug delivery technologies to the forefront of cancer treatment. MOHEDD's journey highlights the collaborative spirit of innovation, merging academia, industry, and clinical expertise to propel cancer therapy into an era of enhanced precision, efficacy, and patient outcomes.